| Identification | Back Directory | [Name]
avosentan | [CAS]
290815-26-8 | [Synonyms]
CS-644
SPP-301
avosentan
Ro 67-0565
Avosentan (SPP301)
RO 67-0565; SPP-301
Avosentan (Ro 67-0565
avosentan,CID 9912992
N-(6-Methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)-pyrimidin-4-yl)-5-methylpyridine-2-sulfonam
N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-5-methyl-2-pyridinesulfonamide
2-Pyridinesulfonamide,N-[6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-5-methyl-
N-(6-Methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)-pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide | [Molecular Formula]
C23H21N5O5S | [MDL Number]
MFCD23843806 | [MOL File]
290815-26-8.mol | [Molecular Weight]
479.51 |
| Chemical Properties | Back Directory | [Boiling point ]
575.5±60.0 °C(Predicted) | [density ]
1.363 | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 6.67 mg/mL (13.91 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | [form ]
Powder | [pka]
3.19±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Avosentan is a competitive antagonist of Endothelin-1 (ET-1) with a high selectivity for the ETA receptor. Avosentan may be a potential option in the treatment of glaucoma. | [Enzyme inhibitor]
This potent, selective and orally available endothelin A receptor blocker (FW = 479.51 g/mol; CAS 290815-26-8; Soluble in DMSO), also known by its code names SPP301 and Ro 67-0565, induces the dose-dependent reduction in the fractional renal excretion of sodium (up to 8.7% at 50 mg avosentan), with a paralleled dose-related increase in proximal sodium reabsorption. Avosentan reduces albuminuria, when added to standard treatment in patients with type 2 diabetes and overt nephropathy, but induces significant fluid overload and congestive heart failure. |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|